Can BCR/ABL breakpoint fusion peptides be used as a target for GVL immunotherapy by expanding peptide specific T cells in patients in vivo?

Rusakiewicz, S., Dodi, I.A., Loconto, J., Travers, P.J. and Madrigal, J.A., 2004. Can BCR/ABL breakpoint fusion peptides be used as a target for GVL immunotherapy by expanding peptide specific T cells in patients in vivo? Blood Cells Molecules and Diseases, 33 (3), p. 191. ISSN 1079-9796

Full text not available from this repository.
Item Type: Journal article
Publication Title: Blood Cells Molecules and Diseases
Creators: Rusakiewicz, S., Dodi, I.A., Loconto, J., Travers, P.J. and Madrigal, J.A.
Date: 2004
Volume: 33
Number: 3
ISSN: 1079-9796
Divisions: Schools > School of Science and Technology
Depositing User: EPrints Services
Date Added: 09 Oct 2015 10:06
Last Modified: 19 Oct 2015 14:27
URI: http://irep.ntu.ac.uk/id/eprint/7819

Actions (login required)

Edit View Edit View

Views

Views per month over past year

Downloads

Downloads per month over past year